Smith & Nephew Plc

Overview

Smith & Nephew was founded in Hull, England in 1856 by Thomas Smith, a pharmacist who initially sold wound dressings. The company has evolved into a multinational medical technology business, listed on the London Stock Exchange and a constituent of the FTSE 100. Deepak Nath, a former Siemens Healthineers executive, became CEO in 2022. The firm's strategy focuses on three core segments: orthopedics (hip and knee replacements, robotic-assisted surgery via its NAVIO system), sports medicine and ENT (arthroscopy, joint repair, and sinus dilation), and advanced wound management (negative pressure therapy, antimicrobial dressings). Smith & Nephew generates roughly $5 billion in annual revenue. The company has a global manufacturing and R&D footprint spanning the US, UK, Ireland, Germany, and China. Known portfolio products include the CORI surgical robot and PICO single-use negative pressure wound therapy. Smith & Nephew employs approximately 18,000 people across more than 100 countries. The company maintains a dual-listed corporate structure but is headquartered in London with major operational hubs in Durham, North Carolina and Park City, Utah. The firm's philanthropic arm, the Smith & Nephew Foundation, supports healthcare education and research. 2024: Deepak Nath outlined a three-year strategic plan to improve margins and accelerate growth in robotics and emerging markets. The structural differentiator is Smith & Nephew's unique hybrid position as both a historic wound-care pioneer and a modern robotic-surgery contender, straddling legacy consumables and high-tech capital equipment. This dual mandate requires the company to manage contrasting R&D cycles and regulatory pathways, a balancing act few pure-play medtech firms face.